Halozyme Therapeutics (NASDAQ:HALO) Issues FY25 Earnings Guidance

Halozyme Therapeutics (NASDAQ:HALO) updated its FY25 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of $4.95-$5.35 for the period, compared to the consensus estimate of $4.83. The company issued revenue guidance of $1.150-$1.225 billion, compared to the consensus revenue estimate of $1.16 billion. Halozyme Therapeutics also updated its FY 2024 guidance to 4.000-4.200 EPS.

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. HC Wainwright reissued a “buy” rating and issued a $68.00 target price on shares of Halozyme Therapeutics in a research report on Monday, December 30th. JMP Securities raised their target price on Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a research report on Friday, November 1st. Wells Fargo & Company lowered Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and upped their price target for the company from $58.00 to $62.00 in a research report on Monday, October 7th. Piper Sandler raised their price objective on Halozyme Therapeutics from $51.00 to $52.00 and gave the stock a “neutral” rating in a research report on Monday, November 4th. Finally, Cowen reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research note on Friday, October 18th. Four investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $61.11.

Halozyme Therapeutics Trading Up 5.0 %

Shares of NASDAQ HALO opened at $53.76 on Friday. The stock has a market cap of $6.84 billion, a price-to-earnings ratio of 17.80, a PEG ratio of 0.44 and a beta of 1.24. The business has a 50 day simple moving average of $50.16 and a 200 day simple moving average of $54.00. The company has a debt-to-equity ratio of 3.32, a quick ratio of 9.15 and a current ratio of 10.36. Halozyme Therapeutics has a 52 week low of $33.15 and a 52 week high of $65.53.

Insiders Place Their Bets

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 10,000 shares of the business’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $50.01, for a total value of $500,100.00. Following the completion of the sale, the director now owns 43,611 shares of the company’s stock, valued at $2,180,986.11. The trade was a 18.65 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 2.70% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.